Spinal muscular atrophy is a severe motor neuron disease caused by inactivating mutations in the SMN1 gene leading to reduced levels of full-length functional SMN protein. SMN is a critical mediator of spliceosomal protein assembly, and complete loss or drastic reduction in protein leads to loss of cell viability. However, the reason for selective motor neuron degeneration when SMN is reduced to levels which are tolerated by all other cell types is not currently understood. Widespread splicing abnormalities have recently been reported at end-stage in a mouse model of SMA, leading to the proposition that disruption of efficient splicing is the primary mechanism of motor neuron death. However, it remains unclear whether splicing abnormalities are present during early stages of the disease, which would be a requirement for a direct role in disease pathogenesis. We performed exon-array analysis of RNA from SMN deficient mouse spinal cord at 3 time points, pre-symptomatic (P1), early symptomatic (P7), and late-symptomatic (P13). Compared to littermate control mice, SMA mice showed a time-dependent increase in the number of exons showing differential expression, with minimal differences between genotypes at P1 and P7, but substantial variation in late-symptomatic (P13) mice. Gene ontology analysis revealed differences in pathways associated with neuronal development as well as cellular injury. Validation of selected targets by RT–PCR confirmed the array findings and was in keeping with a shift between physiologically occurring mRNA isoforms. We conclude that the majority of splicing changes occur late in SMA and may represent a secondary effect of cell injury, though we cannot rule out significant early changes in a small number of transcripts crucial to motor neuron survival.
Autosomal recessive Spinal Muscular Atrophy (SMA) is a leading genetic cause of infant mortality, with a carrier frequency of 1∶50 and an annual incidence of 1 in 10,000 live births [1]. Affected individuals develop symmetrical, proximal weakness resulting from neurogenic muscle atrophy, and ultimately leading, in the most severely affected individuals, to death from respiratory failure. The pathological correlate of these symptoms is selective loss of large alpha motor neurons in the ventral horn of the spinal cord. The vast majority of cases are caused by homozygous deletion of the survival motor neuron 1 (SMN1) gene [2] with subsequent reduction in levels of the SMN protein [3]. SMN is highly conserved in evolution and ubiquitously expressed. Complete loss of SMN, which is incompatible with life [4], is prevented by production of SMN from the SMN2 gene, a near identical paralogue of SMN1 which has arisen from an inverted duplication event in recent evolution. The presence of a translationally silent C-T transition in SMN2 exon 7, however, leads to disruption of an exonic splice-enhancer (ESE) element and exon 7 skipping in the majority of SMN2 derived transcripts [5], [6]. The functional consequence is that SMN2 produces only very little full length SMN (FL-SMN), while the SMND7 isoform is translated into an unstable protein that is rapidly degraded [7]. Disease severity is broadly proportional to residual SMN levels, which is a function of SMN2 copy number, although other modifying factors are involved in some cases [8], [9]. The mechanism by which SMN deficiency leads to selective lower motor neuron loss in SMA is poorly understood and difficult to reconcile with its ubiquitous expression unless either SMN has a motor neuron-specific function or motor neurons are selectively vulnerable to a deficiency in the general function of SMN common to all cells. Currently, the best characterised function of SMN is as part of a multi-protein complex which is critical for the core steps in the assembly of small nuclear ribonuclear proteins (snRNPs), components of the spliceosome, the cellular machinery that controls splicing of pre-mRNAs [10], [11]. In particular, SMN acts in the cytoplasmic assembly of Sm core proteins on snRNAs, which is a prerequisite for import of snRNPs into the nucleus [12]. SMN levels and the activity of snRNP assembly vary during development and according to tissue type. In the mouse spinal cord, snRNP assembly is highest during embryogenesis and early postnatal development and then falls to a baseline level when myelination occurs [13]. Mouse models of SMA, which have reduced SMN levels, show a drop in snRNP assembly activity as measured by in vitro assays, while steady state snRNP levels measured in tissues are only mildly reduced [14]. Interestingly, a subset of snRNPs belonging to the minor spliceosome seems to be differentially affected [14], [15]. Several strands of evidence support the notion that reduced snRNP assembly is associated with motor neuron degeneration. The subtle motor neuron loss that has been reported by some investigators at late stages in mice heterozygous null for Smn can be accelerated by crossing with mice heterozygous null for Gemin2, another core component of the SMN complex. This is associated with a reduction in snRNP assembly [16]. In zebrafish, a failure of embryonic motor axon growth can be induced by silencing not only SMN, but also gemin2. The observed defects can be rescued by direct injection of U snRNPs [17]. However, other studies in zebrafish indicate that the axonal degeneration phenotype is not coupled to U snRNP assembly [18]. Reducing SMN levels in HeLa cells by RNAi leads to an increased error rate in splice-site pairing, which has also been observed in fibroblasts from SMA patients [19]. Finally, a recent study in SMA mice found that at end-stage, widespread splicing abnormalities can be found in several tissues including the spinal cord. Importantly, different transcripts were found to be altered in a tissue-specific manner [15]. While both snRNP assembly dysfunction and splicing abnormalities have been documented in models of SMA, several questions remain. It is still unclear whether splicing abnormalities cause motor neuron loss in SMA, or whether they are a late occurrence in disease, either as a consequence of spliceosome dysfunction or the severe physiological alterations secondary to respiratory distress, hypoxia and malnutrition. If spliceosome dysfunction is critical for disease pathogenesis, the mechanism of splicing alterations needs to be further delineated. In addition, the role of SMN in spliceosome assembly is only one of many functions that are potentially altered in SMA, including roles in transcription regulation [20]–[22], axonal transport of mRNA and RNPs [23], [24] as well as regulation of local translation at the neuromuscular junction [25]. This study had two aims. First, we wanted to address the question of whether abnormal splicing events are a cause or consequence of SMA. We utilised an exon-specific microarray to examine the transcriptome of spinal cord samples harvested from SMA and control mice at pre-symptomatic, early symptomatic and late-symptomatic stages, to test the hypothesis that widespread alteration of splicing precedes disease onset. Secondly, we used the difference in temporal mRNA expression pattern between SMA and control mice to identify neuronal pathways disturbed by SMN deficiency.
The mouse model used in this study (Smn−/−; SMN2; SMNΔ7) is the most commonly used model of severe SMA and has been described previously [26]. The maximum lifespan of SMA mice was 14 days. Subtle differences in weight compared to the control littermates (Smn+/+; SMN2; SMNΔ7) were discernible before P7, but were not reliably predictive of genotype in individual mice (Figure 1A and 1B). SMN protein levels were markedly reduced in SMA mice at all time points as measured by Western blot (Figure 1C) and immunohistochemistry (Figure 1D). At P7 a failure in the righting reflex became apparent. Importantly, this coincided with a drop in numbers of large motor neurons in the spinal cord (Figure 2A and 2B). No discernible differences in phenotype or pathology were present at P1, indicating that, in the SMNΔ7 mouse model of SMA, the disease develops in a motor system in which embryonic development has been relatively normal. By P13, mice appeared emaciated, were unable to right themselves, and showed signs of respiratory distress (Figure 1B). There was a corresponding loss of >30% of lower motor neurons from the ventral horn in SMA mice. At late-symptomatic stage (P13), a similar relative loss of motor neurons was evident across the entire length of the spinal cord, (Figure 2C), justifying the use of whole spinal cord for RNA analysis. However, absolute numbers differed depending on the region examined, reflecting the differential innervation of limb and trunk musculature by motor neurons originating in the cervical, thoracic or lumbar cord. To understand the scale of change in mRNA expression in the spinal cord, we first performed gene-level comparisons between genotypes at each time point, using the core probe sets on the array and GeneSpring software (Agilent Technologies, Santa Clara, CA, USA). When using an arbitrary p-value threshold of 0. 05 and a fold-change threshold of 1. 5 as cut-off for biological significance, the expression of 142 genes was increased or decreased in the spinal cord of SMA mice compared with their control littermates at late-symptomatic stage (P13), with a maximal fold-change of 3. 9 (Table S1). Importantly, the degree of change between SMA and control mice was much smaller at the pre-symptomatic (P1) and early-symptomatic (P7) stages, with only 12 and 23 genes changed, respectively (Table 1 and Table 2; Figure 3A). This finding argues against a critical function of SMN in transcription regulation, but also shows that if widespread splicing changes occur in SMA, this does not lead to a pre-symptomatic systemic change in whole transcript level mRNA expression, which might be expected if mis-spliced transcripts are subject to nonsense-mediated decay. An additional data analysis, which we refer to as the ENSG analsysis, was performed in which probes were grouped into sets, each corresponding to a gene in the Ensembl (version 49) annotation database [27]. Time point-specific differential expression between cases and controls was quantified by fitting a linear model on a gene-by-gene basis [28], [29]. Of 21,911 genes examined, 693 genes exhibited case/control differences at P13, as opposed to 92 at P7, and 83 at P1 (Figure S1, Tables S2, S3, S4, see Text S1 for details of the linear model). This is in accordance with the parallel analysis described above. We next examined changes between time points for each genotype. Overall, the number of genes differentially expressed between time points in control mice was higher by a factor of ten compared to the number of genes differentially expressed between genotypes at individual time points (Figure 3B), suggesting that the immediate post-natal period is associated with major changes in spinal cord gene expression in normally maturing mice. A key aim of this study was to assess the amount of splicing variation in the spinal cord of an SMA mouse model compared to control mouse spinal cord at several time points during disease progression. Because exon-specific microarrays are relatively novel, and analysis methods have not been fully developed and validated, we used two complementary statistical approaches to investigate the number of differentially expressed exons. First we used an ANOVA test in GeneSpring (Agilent) to select exons which show a significant difference between exon-level and transcript-level signal and then calculated the splicing index (SI) [30], for these exons. The SI is the logarithm of the ratio of array probe set intensities (corresponding to expression levels of individual exons) to overall gene-level expression. So an SI value of 0 indicates equal expression of a particular exon in relation to the gene as a whole between genotypes i. e. no differential alternative splicing. Using a splicing index of |SI|≥0. 5 as an arbitrary threshold we identified 252 potential alternative splicing events at the late-symptomatic stage (P13), but only 5 at the early symptomatic (P7) and 16 at the pre-symptomatic (P1) stage (Figure 4A). This initial analysis suggests that alternative splicing events are a consequence of disease progression in SMA, rather than the primary cause. Since the splicing index method is known to lead to inaccuracies if complex splicing patterns are present, such as splicing of multiple exons in one gene, and might thus underestimate the level of differential exon use present, we next performed an analysis comparing expression levels of individual exons between genotypes at each time point. The rationale for this is that each instance of differential splicing between genotypes will lead to at least one exon being differentially expressed. So the number of differentially expressed exons provides an upper bound for the number of differential splicing events. In this analysis, which we refer to as the ENSE analysis, probes were grouped into sets, each corresponding to an Ensembl exon [27]. Time point-specific differential expression between cases and controls was quantified by fitting a linear model on an exon-by-exon basis [28], [29]. The p-value cut-off for significant differences between genotypes at the exon-level was chosen to balance sensitivity with a reasonable false discovery rate (FDR), as estimated by a permutation-based analysis (Text S1 and Table S5). At a p-value threshold of 1e-4, there were 812 significantly differentially expressed exons at P13, compared to 66 at P7, and 72 at P1 (Figure 4B, Tables S6, S7, S8); a total of 211,567 exons were examined. See Materials and Methods and Text S1 for further details of this analysis. This provided additional evidence that the vast majority of alternative splicing events occur at late-stage disease in the SMNΔ7 mouse model of SMA. We further observed that for genes with at least one differentially expressed probe set under the ENSE annotation, but no significant gene-level change under the ENSG annotation, i. e. genes for which there is some evidence of differential splicing events, it is mostly one, and never more than two, exons that are significantly altered. To assess whether the differentially expressed exons were associated with a particular intron type, we cross-referenced our data with a publicly available database of U12 introns, i. e. sequences recognised by the U12 snRNA containing minor spliceosome, but not the U2 snRNA containing major spliceosome [31]. Overall, the frequency of U12 introns in genes containing exons differentially expressed between genotypes was 0. 19%, as opposed to the expected frequency of approximately 0. 35% (0. 13% at P1,0% at P7,0. 22% at P13). Moreover, only one gene (Vash1, ENSG000000712460, Vasohibin-1) contained a differentially expressed exon directly adjacent to an U12 type intron, while all other exons were remote from U12 type introns. This analysis suggests that genes spliced by the minor spliceosome are not preferentially affected by SMA, even though components of the minor spliceosome were shown to be disproportionately affected by SMN deficiency [14]. While the results obtained from the SMNΔ7mouse model afforded important insights into the dynamics of gene- and exon-level expression changes over time, to ensure that our findings were not restricted to this particular transgenic model of SMA, but applicable to SMA mouse models in general, we performed a similar analysis on the more severe but genetically less complicated Smn−/−; SMN2 mouse model of SMA [32]. The Smn−/−; SMN2 animals, in which complete absence of mouse Smn is rescued by the introduction of the human SMN2 transgene, have a maximum lifespan of 6 days. Previous studies showed that at P1, there are normal motor neuron numbers, whereas at P5, there is about a 35% loss compared to litter mates with normal mouse Smn (Smn+/+; SMN2) [32]. Early synaptic abnormalities are seen from P2 in this model [33], although neuromuscular junctions appear normal at P1, indicating normal pre-symptomatic development [34]. Exon-array analysis of spinal cord harvested from pre-symptomatic (P1) and late-symptomatic (P5) animals mirrored the principal findings in the SMNΔ7 mouse at both gene and exon level. When examining gene expression in Genespring using core probe sets, more changes were present at late-symptomatic stage than at the pre-symptomatic stage (3 genes up- or down-regulated at P1,160 genes up- or down-regulated at P5 with p≤0. 05 and fold change >1. 5). Even more striking was the result of the splicing index analysis, which showed 27 potential alternative splicing events at P5, but none at P1 when choosing a splicing index cut-off of 0. 5. These results showed that our findings in the SMNΔ7 mouse model were not caused by a specific effect of the SMNΔ7 transgene but are likely to be a generalised phenomenon in SMA. To validate the findings of our microarray experiments, we performed semi-quantitative and/or quantitative RT-PCR focussing on genes that showed at least one exon with differential expression at all time points (Cdkn1, Snrp1a, Chodl, Mccc2, Uspl1, ChAT, Figure S2). In addition, we performed qRT-PCR on spinal cord samples obtained from E16 embryos for some of the targets to examine whether changes were already present pre-natally. All qRT-PCR results matched the changes at gene-level seen in the array experiments, underlining the robustness of the array findings. Chodl, the gene encoding chondrolectin is a C-type lectin with unknown in vivo function. Interestingly, in situ hybridisation shows that this gene is highly expressed in anterior horn cells (Allen Brain Atlas http: //mousespinal. brain-map. org) and might have important, if currently unknown, motor neuronal functions. We observed a progressive reduction in Chodl expression over time. Of note, the exon array data were indicative of differential expression of the 3′ end of Chodl, and validation by qRT-PCR using primers spanning both constitutive exons as well as two alternative 3′-terminal exons was in keeping with a preferential loss of the Chodl -001 isoform (ENSMUST23568) and relative sparing of Chodl-002 (ENSMUST69148) (Figure 5A and 5B). The relative reduction of Chodl expression appeared to be spinal cord specific and could not be demonstrated in either skeletal muscle or kidney. However, even these tissues showed a trend towards increased expression of the Chodl-002 isoform in SMA compared to control mice (Figure 5C). Immunohistochemistry for Chodl showed strong immunoreactivity of anterior horn cells, in keeping with the published in situ data. There was reduced Chodl immunoreactivity in SMA mice, but remaining anterior horn cells retained substantial Chodl staining, which indicated that the reduced Chodl expression is at least partially due to loss of motor neurons (Figure S4). Uspl1 (ubiquitin specific peptidase like 1), a gene encoding part of the ubiquitin-dependent protein degradation pathway was found to be up-regulated in SMA at all time points. In addition, Uspl1 showed a consistent change in both splicing index and Ensembl exon-level analysis of differential splicing. Uspl1 exon 2 (ENSMUSE00000351955) is a cassette exon absent in transcripts Uspl1-006 (ENSMUST00000121416) and -007 (ENSMUST00000117878). The increased use of Uspl1 exon 2 in the SMA mice led to an isoform shift with relatively higher levels of exon 2 containing transcripts Uspl1 -001-005 (Figure 6). Of note, this pattern was much more pronounced in muscle than in spinal cord, and less evident in kidney (Figure 6B). In spinal cord samples, the degree of isoform shift was more pronounced at symptomatic than at pre-symptomatic stages (Figure 6C). Immunohistochemistry for Uspl1 showed ubiquitous cytoplasmic staining in all spinal cord cells with grey matter preference. In keeping with the only mild overall increase in Uspl1 expression at mRNA level (Figure S2F), no difference in immunoreactivity was evident between genotypes Figure S4) and Western blotting showed no significant difference in the main protein isoform identified between genotypes. Further interesting changes at all time points were detected including the whole-gene up-regulation of Snrpa1 (average 1. 8 fold). Snrpa1 encodes one of the many protein components of the spliceosomal A complex [34], which is associated with the U2 snRNA. Western blotting showed a consistent small expression increase (Figure S4). While no other spliceosomal components were differentially expressed, the Snrpa1 change might reflect a compensatory response of the cell to Smn deficiency. Another change included down-regulation of isoforms ENSMUST00000091326 and ENSMUST00000022148 of Mccc2, the gene encoding the methylcrotonoyl-CoA carboxylase beta chain, a mitochondrial enzyme involved in amino acid metabolism (Figure S2D). Interestingly, the array data suggest that, while two Mccc2 isoforms were expressed at lower levels in SMA compared to controls, a third isoform (ENSMUST00000109383) was in fact up-regulated. This was confirmed by qRT-PCR and semi-quantitative PCR (Figure S3). In the SMNΔ7 mouse model, the early postnatal days appeared particularly relevant to disease development. Our earlier finding of massive gene expression changes between time points in post-natal wild-type mice (Figure 3B) indicates that events relevant to disease in the SMN Δ7 mouse model coincide with transcriptome changes associated with normal post-natal development or maturation. To analyse which pathways were physiologically activated during this time, we first compared gene expression in control mice (Smn+/+; SMN2; SMNΔ7) between P1 and P7, and subsequently between P7 and P13. Using GO-Elite software, we identified pathways enriched with genes involved in spinal cord cell proliferation, axon development, oligodendrocyte development and myelination as significantly altered, reflecting physiological events during the rapid growth of the spinal cord. When the same analysis was performed for the SMA mice, a strikingly different pattern emerged. With the exception of two GO IDs pertaining to nervous system development, all physiologically activated pathways were absent in both the P1 v P7 and P7 v P13 analyses Table 3). To investigate whether this dramatic change in gene expression pathways was mirrored by a difference in proliferating spinal cord cells, we performed Western blotting and immunohistochemistry for the proliferation marker PCNA. Our preliminary results indicate that there is indeed a reduction in the number of proliferating cells in the SMA spinal cord (Figure S5). At P13, genes relating to cellular responses to DNA damage became prominent in the SMA mice, which could not be explained by a significant amount of spinal cord gliosis (Figure S5). Of note, the gene with the highest-fold change between genotypes at P13 was Cdkn1a, a cyclin dependent kinase inhibitor activated by p53 in response to DNA damage. This analysis suggested that in the SMNΔ7 mouse model there is an inhibition or a failure of activation of the normal physiological pathways of post-natal spinal cord maturation.
In this study we undertook a detailed assessment of transcriptional changes over time in the spinal cord of a commonly used severe mouse model of SMA, using time points correlated with key phenotypic and pathological changes. We identified alterations in a subset of genes involved in post-natal neurodevelopmental pathways in SMA, and showed that splicing alterations are only a late occurrence in disease. Survival, weight development and motor phenotype of our SMNΔ7 mouse colonies were similar to that described by others [26], [35], with a change in outward appearance and development of motor deficits apparent at P7. Recent studies have identified morphological changes at the neuromuscular junction as early events in SMA [33], [35] with neurofilament accumulation occurring as early as P5 in the SMNΔ7 model. This structural change at the distal end of the motor neuron is closely followed in our study by a significant loss of large motor neurons at P7, indicating that although synaptic changes are the earliest identified feature of SMA it ultimately is a disease of the entire lower motor neuron. Of note, motor neuron loss was present to a similar degree across the entire spinal cord, in contrast to the previous finding of a rostral-caudal gradient with relative sparing of the lumbar region [35]. Motor neuron loss at P7 was reflected in the reduction at transcript level of choline acetyl transferase (ChAT), the key enzyme in motor neuronal synthesis of acetylcholine (Figure S2E). This finding, as well as that of reduced levels of Chodl mRNA, which seems to be highly expressed in anterior horn cells, shows that even though whole spinal cord was used for the array, important cell-type specific changes were detectable. The key finding of this study is that alternative splicing events are a late occurrence in SMA, and are therefore unlikely to contribute to early disease pathogenesis. Zhang et al. [15] described widespread splicing abnormalities in several tissues including the spinal cord at end-stage disease in the same mouse model employed in this study and attributed this finding to dysfunction of the spliceosome secondary to SMN deficiency. Importantly, even though the time point of analysis is not absolutely identical to ours, there is considerable overlap between Zhang et al.' s data set obtained at P11 and our P13 data set, when raw data are analysed in the same way (Figures S6, S7; Tables S1, S9, S10, S11). However, it remains unclear from these data whether splicing abnormalities had preceded the onset of symptoms, as would be predicted from the crucial role of SMN in spliceosome assembly, particularly in embryonic and early post-natal development [13]. In addition, the presence of widespread splicing defects in organs other than the spinal cord is difficult to interpret in the light of apparent tissue specificity of the disease if splicing abnormalities are indeed thought to be relevant to the mechanism of motor neuron degeneration. To determine the degree of variation in splicing between SMA and control mice, we utilised the splicing index, but also examined changes at individual exons as a measure of the maximum number of alternative splicing events present. The absolute number of changes found in late-symptomatic mice was not large given the large number of exons examined (>200,000). When the same analysis was performed, comparing between genotypes at pre-symptomatic and early symptomatic time points, only very few exon-level changes were present. Importantly, we were able to confirm a similar pattern of exon expression changes in the more severe Smn−/−; SMN2 mouse model, corroborating our main finding in the SMNΔ7 mice. Overall, our data indicate that the majority of splicing changes are not a direct consequence of SMN deficiency, but rather a consequence of disease progression, probably representing physiological isoform-shifts in response to cell stress. There is evidence that oxidative stress can induce shifts in alternative splicing, and that neurons may be more vulnerable to this process than other cells [36]. We would therefore argue that SMN deficiency to the degree observed in either the SMNΔ7 or Smn−/−; SMN2 mouse, although associated with severe reduction in snRNP assembly capacity in vitro [14], does not lead to a systemic breakdown of splicing fidelity in vivo until the disease is well established. While our results do not support the hypothesis that widespread, systematic splicing abnormalities cause SMA, we cannot rule out the possibility that splicing of one or several transcripts is critically affected by SMN deficiency, and that the few splicing changes observed early in our mice contribute to SMA pathogenesis, followed by a cascade of loss of splicing fidelity or secondary effects. In fact, at least one of the genes identified by our array (Uspl1) is differentially spliced between SMA and control mice even at the embryonic phase, albeit to a lesser degree than at the symptomatic stages. Of note, the isoform shift observed in this particular gene is more pronounced in muscle than in spinal cord, and less marked in kidney, an organ not affected by SMA pathology. Independent of whether or not splicing changes are ultimately responsible for SMA disease initiation, our study identified several pathways that might shed light on SMA pathogenesis and disease progression. Analysis of transcriptional changes between genotypes in this study took place on a background of large scale physiological changes between time points, reflecting rapid neuronal development in the early post-natal days. Analysis of the changes between time points identified several pathways related to normal neuronal development. Surprisingly, in the SMA mice the majority of physiological transcriptional changes seen in control mice were absent even between the early time points P1 and P7. This finding not only indicates that abnormal post-natal neuronal development might underlie early events in SMA but might explain general delayed growth and failure to thrive in the SMA mice. In this study, we examined gene expression in the entire spinal cord and are unable to distinguish which cell types contribute most to expression changes, even though changes that plausibly originate from motor neurons, such as ChAT and Chodl, are clearly present. The neurodevelopmental pathways identified as altered in our study can be associated with other cell types, including oligodendrocytes and cells in the posterior spinal cord. While this is a preliminary finding, it clearly warrants further studies examining the role of non-motor neuronal cells in SMA. Human autopsy cases indicate involvement of sensory neurons in the dorsal root ganglia, Clarke' s column and the thalamus in SMA [37]–[40], although the majority of studies were undertaken before the molecular diagnosis of SMA was available. More recent clinical studies showed that severe SMN-related SMA is associated with widespread neuronal degeneration, including sensory pathways [41]. Subtle sensory neuron abnormalities have also been detected in a severe mouse model of SMA [42]. To our knowledge, however, there is no study systematically investigating the role of non-motoneuronal cells in SMA spinal cord. In conclusion, our data show that alternative splicing events predominantly occur late in SMA, while alterations of post-natal neurodevelopmental pathways precede overt symptom onset. Further studies should continue to focus on the role of SMN in the post-natal maturation and development of the neuromuscular system including spinal cord motor neurons.
Transgenic Smn+/−; SMN2; SMNΔ7 [26] mice were maintained as heterozygous breeding pairs in standard animal facilities in Oxford. Homozygous Smn−/−; SMN2; SMNΔ7 mice reached the disease end-point by post-natal day 13 (P13). Five mice of each genotype were sacrificed at age P1, P3, P5, P7, P9, P11 and P13 for motor neuron counts, and 4 mice of each genotype at P1, P7 and P13 for RNA and protein extraction. Mice were genotyped using DNA extracted from tail-tips and standard PCR procedures. For motor neuron counts, mice were terminally anaesthetised with i. p. pentobarbitone and transcardially perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. For RNA and protein extraction, mice were killed by i. p. injection of pentobarbitone. Smn+/−; SMN2 mice (Jackson labs strain no. 005024) were maintained as heterozygote breeding pairs under standard SPF conditions in animal care facilities in Edinburgh [43]. Litters produced from SMA colonies were retrospectively genotyped using standard PCR protocols (JAX® Mice Resources). All animal breeding and procedures were performed in accordance with Home Office and University guidelines. Spinal cords were dissected, post-fixed in 4% PFA for 2 hours, cryoprotected in 30% sucrose overnight, embedded in OCT medium and rapidly frozen in liquid nitrogen-cooled isopentane. 20 µm thick horizontal sections were cut on a cryostat and stained with 0. 5% Cresyl violet with 0. 04% acetic acid. A minimum of 30 non-adjacent sections covering the entire spinal cord segment of interest were scrutinised for large, polygonal, Nissl positive cells in the ventral horn of the spinal cord anterior to the central canal. Only cells with a clearly present nucleolus were counted to avoid double counting of neurons. Motor neuron counts were performed blinded to genotype. At P13, cords were macroscopically divided into cervical, thoracic and lumbar segments using the cervical and lumbar enlargements as landmarks. For the time-course, only lumbar spinal cord was utilised. 6 µm thick paraffin section were cut and stained with standard Haematoxylin and Eosin. For immunohistochemistry, sections were incubated with the primary antibody (mouse anti-SMN antibody (1∶320, BD Transduction lab), rabbit anti-Uspl1 (1∶600, Santa Cruz), mouse anti-Chodl (1∶200, abcam), rabbit anti-PCNA (1∶2500, abcam), goat anti-Chat (1∶400, Chemicon) for 40 minutes at room temperature or at 4°C overnight. Antibody binding was visualised using a Dako REAL EnVision kit according to manufacturer' s instructions. Immunohistochemistry was carried out on several sections taken from two different paraffin blocks for two animals per genotype. Representative images are shown. Whole spinal cords were rapidly dissected and snap-frozen on dry ice. RNA was extracted using the Qiagen RNeasy Mini RNA extraction kit according to the manufacturer' s instructions. The quality and RNA integrity was assessed on a BioAnalyzer; all samples had a RNA Integrity Number (RIN) ≥9 (Agilent Laboratories, US). 1 ug starting RNA was ribosome depleted using the Ribominus Human/MouseTranscriptome Isolation kit (Invitrogen). Labelled sense ssDNA for hybridization was generated with the Affymetrix GeneChip WT sense target labelling and control reagents kit (Affymetrix, UK) according to the manufacturer' s instructions. Sense ssDNA was fragmented and the distribution of fragment lengths was measured on the BioAnalyzer. The fragmented ssDNA was labelled and hybridized to the Affymetrix GeneChip Mouse Exon 1. 0 ST Array (Affymetrix). Chips were processed on an Affymetrix GeneChip Fluidics Station 450 and Scanner 3000. For the gene-level analysis, core probe sets which map to the same transcript cluster were grouped together and RMA (Robust multi-array analysis) [44] normalised in GeneSpring GX10. 1. 02. Differentially expressed genes were identified using an unpaired t-test; selecting genes with 1) a p-value less than or equal to an arbitrary threshold of 0. 05 and 2) a fold change difference between genotypes ≥1. 5. The selected genes were sorted according to gene ontology using GenMAPP' s GO-Elite (http: //www. genmapp. org/go_elite/go_elite. html). Only MAPPFinder ontologies with ≥3 genes changing and a permuted p-value of ≤0. 05 were reported. At the exon level, core probe sets were PLIER (Probe Logarithmic Intensity Error) normalised in GeneSpring GX 10. 1. 02 (Agilent). Transcript probe sets that had detection above background (DABG) p-value≤0. 05 in both SMA and control groups were retained. An ANOVA test was used to identify significant differences between exon-level signal and transcript level signal. As recommended in the Affymetrix White Paper [44], [45], exon level probe sets exhibiting exon-to-transcript intensity ratios >5 were excluded from the ANOVA (where log2[exon-to-transcript ratio] = log2[exon expression]−log2[transcript expression]). This filter removed probes with high background and cross-hybridisation potential. The p-value threshold for the ANOVA was selected to control for a false discovery rate of 0. 05 using the Benjamini-Hochberg multiple testing procedure [46]. For exons selected on the basis of the ANOVA, the spicing index, SI (log2[exon-to-transcript expression ratio]), was calculated and used as a measure of differential splicing between genotypes. See [45], [47] for further details. A significantly differentially spliced exon was defined to be one having both an FDR-controlled ANOVA p-value≤0. 05 and |SI|≥0. 5 (on the log scale, corresponding to a fold change up or down of approximately 1. 4 in the absolute exon/transcript ratio between genotypes). CEL files were preprocessed using RMA without background correction (see Text S1). Publicly available custom chip-definition files (CDFs) (http: //brainarray. mbni. med. umich. edu/Brainarray/Database/CustomCDF/CDF_download. asp) were used to group probes into sets. Parallel analyses, based on two different CDFs were performed. The first CDF, referred to as ENSE, defines a probe set for each Ensembl exon. The second, ENSG, defines a probe set for each Ensembl gene [27]. There were 211,567 and 21,911 probe sets for the ENSE and ENSG analyses respectively. At each probe set, a linear model was fitted using the limma package (version 2. 16. 5), to quantify evidence of genotype differences within each time point (see Text S1 for details). A permutation-based analysis was conducted to estimate the FDR at a variety of p-value thresholds (see Text S1 and Table S5). The p-value thresholds selected were 1e-4 for ENSE, and 1e-3 for ENSG, as these thresholds controlled the FDR at a reasonably low level. Statistical analyses were performed using R [28], version 2. 8. 1. Snap frozen whole spinal cords were homogenised in RIPA lysis buffer (50 mM Tris-Cl, pH 7. 5,150 mM NaCl, 0. 1% (w/v) SDS, 1% (v/v) sodium deoxycholate, 1% (v/v) TX-100) and 1% (v/v) protease inhibitors by sonication at 50% output for 15 sec. Homogenates were chilled on ice for 20 min and clarified by centrifugation at 15,800 g for 20 min at 4°C. Protein samples (50 µg/well) were electrophoresed through 12% SDS polyacrylamide gels and transferred to 0. 2 µm nitrocellulose membranes (Millipore). Membranes were blocked with 5% (w/v) milk powder in TBS-T, pH 8. 0, for 1 hr and incubated with the primary antibody (mouse anti-SMN (1∶1,000, BD Transduction labs), mouse anti-actin (1∶1,000, Abcam), rabbit anti-SNRPA1 (1∶1000, abcam), goat anti-CHAT (1∶500, Chemicon), rabbit anti-USPL1 (1∶500, Santa Cruz), rabbit anti-PCNA (1∶200, abcam) in 3% (w/v) BSA in TBST overnight at 4°C. Blots were probed with HRP-conjugated antibodies (1∶10,000, Amersham) and developed using ECL reagents (Amersham). Western blots were repeated three times on biological replicates, and representative blots are shown. RNA was reverse transcribed into cDNA using random hexamer primers (Invitrogen) and Expand Reverse Transcriptase (Roche) under standard conditions. RT-PCR was performed using Taq DNA Polymerase (Sigma) or Expand High Fidelity PCR system (Roche). Real-time PCR was performed using Fast SYBR Green chemistry (Applied Biosystems) and a StepOnePlus Real-time PCR machine (Applied Biosystems). Real-time PCR Primers were designed with Primer Express software (Applied Biosystems). Primer concentrations were optimised to yield low Ct values and minimal primer dimer formation (commonly 300 nM for both forward and reverse primers). GAPDH was used as the endogenous control, as there was no differential expression between genotype in the array and in qRT-PCR experiments. All primer pairs were tested to have similar amplification efficiency to GAPDH when tested on serial cDNA dilutions over 4 log. Fold change was calculated using standard ΔΔCt calculations. The average fold change per time point was calculated from four biological replicates at each time point, and an unpaired two-tailed t-test was used to test for significantly different gene expression at each time-point. Error bars represent the standard deviation of the mean.
The identification of mutations in the Survival Motor Neuron (SMN) gene as the cause of the severe motor neuron disorder spinal muscular atrophy is one of a number of discoveries implicating selective motor neuron vulnerability to defects in processing of RNA and its associated ribonucleoprotein complexes. An unresolved issue is whether loss of the general cellular function of SMN in spliceosomal assembly, which is predicted to result in widespread defects in mRNA splicing, is directly responsible for motor neuron death. We have used exon-specific microarrays to assess the degree of altered splicing in the spinal cord in a mouse model of SMA. Our finding that the vast majority of splicing changes are a late feature of the disease and may represent a shift to alternative isoform expression, rather than loss of splicing fidelity, provides evidence that widespread splicing disturbance is not a primary feature of the disease pathogenesis but a secondary effect of cell injury in a late phase of the disease. However, our study cannot rule out a role for subtle early changes in one or a few transcripts crucial to motor neuron survival expressed at low levels or in only in a sub-population of spinal cord cells.
neurological disorders/neuromuscular diseases
genetics and genomics/gene expression
genetics and genomics/disease models
genetics and genomics/genetics of disease
neuroscience/neurodevelopment
neurological disorders/neurogenetics
neuroscience/neurobiology of disease and regeneration
Alternative Splicing Events Are a Late Feature of Pathology in a Mouse Model of Spinal Muscular Atrophy